silent atrial fibrillation; atrial high-rate episodes
Jump to navigation
Jump to search
Introduction
- atrial high-rate episodes represent a potentially heterogenous group of atrial arrhythmias detected by implantable cardiac devices
- prior atrial fibrillation on surface electrocardiogram
Clinical trials
- ARTESiA trial
- CHA2DS2-VASc score > 4, apixaban resulted in 1.3 fewer episodes of stroke or systemic embolism per 100 patient-years without significant increase in bleeding
- CHA2DS2-VASc score of <= 4 or less, reduction in stroke or systemic embolism withh apixaban not statistically significant
More general terms
References
- ↑ Kirchhof P et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023 Aug 25; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37622677 https://www.nejm.org/doi/10.1056/NEJMoa2303062
- ↑ Wong JA, Conen D, Van Gelder IC et al. Progression of device-detected subclinical atrial fibrillation and the risk of heart failure. J Am Coll Cardiol 2018 Jun 12; 71:2603. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29880119
Glotzer TV. The cacophony of silent atrial fibrillation. J Am Coll Cardiol 2018 Jun 12; 71:2612. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29880120